In this context, combination treatments with drugs causing non-genotoxic activation of p53 oligomerisation and FDA-approved RAF inhibitors, such as Sorafenib, represent potential therapeutic candidates for tumours associated with HERC2 deficiency. This evidence concerns the gene HERC2 and neoplasm.